Toll-Like Receptor-Targeted Anti-Tumor Therapies: Advances and Challenges

The document reviewed the role of Toll-like receptors (TLRs) in anti-tumor therapies, highlighting their dual role in promoting and inhibiting tumor growth. TLR-targeted therapies showed promise in cancer treatment, with some TLR agonists approved by the FDA, but faced challenges such as limited clinical translation and safety concerns. Advances included the development of novel TLR agonists and their incorporation with nanotechnology, as well as multi-agent treatments to enhance efficacy. TLRs like TLR3 and TLR4 were noted for their potential in cancer immunotherapy, though the complexity of TLR signaling pathways posed significant challenges. The document emphasized the need for further research to optimize delivery methods, understand TLR expression patterns, and develop personalized medicine approaches in cancer therapy.